**Core tip:** Differentiating normal from pathologic liver fat storage in children could depend on technical measurements. Using MR-spectroscopy, a cut-off value of 6% demonstrates the best diagnostic performance, otherwise magnetic resonance imaging (MRI)-PDFF cut-off value of 3.5% better discriminates normal weight from obese children. It is confirmed that MRS is an accurate and precise method for detecting non-alcoholic fatty liver disease in children. However, MRI-PDFF- is a feasible alternative to MRS for quantifying liver steatosis.

INTRODUCTION
============

Non-alcoholic fatty liver disease (NAFLD) is emerging as a leading cause of chronic liver disease in children and adolescents, with a prevalence in the general population ranging from 3%-10% in normal weight children and 80% in obese children\[[@B1]-[@B2]\]. Children with NAFLD are usually asymptomatic and garner clinical attention because of elevated liver enzymes or fatty liver being observed during an ultrasound examination. The measurement of liver enzymes alone is not sufficient for accurate fatty liver screening in overweight children because enzymatic abnormalities correlates poorly or not at all with early steatosis\[[@B3],[@B4]\]. At present, liver biopsy represents the reference standard for diagnosing liver steatosis, although the drawbacks of this invasive technique are well known. It is associated with morbidity and mortality, it has sampling errors, and it is not appropriate for screening, longitudinal monitoring, or evaluating treatment response\[[@B4]\]. Among the currently available imaging modalities, magnetic resonance imaging (MRI) and ¹H MR spectroscopy (MRS) are the most reproducible, safe, and accurate imaging techniques that can be used in clinical trials and epidemiologic studies\[[@B5]\]. However, MRS has limited clinical applicability or availability because it requires sophisticated post-processing methods, and not every MRI is routinely equipped with MRS capabilities. Recent improvements in MRI can provide the magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), which is a novel biomarker that has demonstrated robust correlation and equivalency with MRS\[[@B6]-[@B10]\]. In addition, MRI-PDFF allows fat mapping of the entire liver, and it can be used with any clinical MRI platform, whereas MRS measures fat biochemically in small regions of interest (ROIs). To the best of our knowledge, few studies have used MRS and histology to investigate liver fat content in adolescents\[[@B11]-[@B14]\]. A recently published paper suggested similar fat-storage between overweight children and adults, and the study proposed the same cut-off value for normal and pathologic storage\[[@B15]\]. The aim of our study was to validate a cut-off value for a pediatric population and to correlate the data with laboratory/chemistry results and subcutaneous and visceral adipose tissue (SAT and VAT) findings.

MATERIALS AND METHODS
=====================

The study has been approved by the ethics committee, and written informed consent was obtained from all participants and their legal guardians before the study began. From October 2013 to December 2014, 93 Caucasian obese children and adolescents \[body mass index (BMI) above the 95^th^ percentile for age and gender\] were referred to the Hepatology Outpatient Unit of the Department of Pediatrics to confirm or rule out the presence of NALFD. All enrolled subjects underwent the following measurements: fast blood samples \[glucose, cholesterol, triglycerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST), insulin and and γ-glutamyl transferase (γ-GT)\] and BMI. They also underwent MRI to quantify liver steatosis and evaluate SAT and VAT. Five children were excluded because their data imaging was not suitable for post-processing due to several motion artifacts. The study population included 27 patients (16 males and 11 females; mean age, 13 years; range, 9-18 years) who were scheduled for liver biopsy to assess the presence of nonalcoholic steatohepatitis (NASH) or other liver diseases. Liver biopsy was performed within two weeks of the MR examination to avoid any bias, such as diet modification. An age- and sex-matched control group of 27 healthy Caucasian children, who also had blood chemistry results available, were recruited (11 males and 16 females; mean age, 12 years; range 8-18 years).

MR imaging
----------

MRI exams were using a 3T magnet system (GE Discovery 750; General Electric Healthcare, Milwaukee, WI, United States), with a peak gradient amplitude of 50 mT/m and a 200 μsec time to peak. An eight-element body torso-array coil system was used. Before the spectroscopy acquisition, a T2-weighted image in the coronal plane (TR 1300, TE 125, FA 90°, slice thickness 6 mm, matrix 288 × 192) and a T1-weighted axial image (TR 4 ms/TE 1 ms, FA 60°, slice thickness 6 mm, matrix 288 × 192) were acquired. To quantify the hepatic fat fraction (HFF), an axial breath-hold low-flip angle, T1-weighted, 2D multiple-echo, spoiled gradient-echo (GRE) sequence (TR5.1/TE from 0.8 to 3.8, flip angle 5°, field of view 33 cm; section thickness, 10 mm; intersection gap, 0, matrix 128 × 128, acquisition time 2 × 17 s) was used was used. MRS was performed using one 20 mm × 20 mm × 20 mm voxels placed in segment VI-VII (as close as possible to the site of liver biopsy) and avoiding the artifact, major blood vessels and biliary ducts. All spectra were obtained in the stimulated echo acquisition mode (STEAM, TR 4000 ms), using a breath hold sequence with an acquisition time of approximately 24 s. Field homogeneity was automatically adjusted for each voxel. The T2 relaxation times of both metabolites were determined from their peak amplitudes at each echo time using an exponential least-squares fitting algorithm, and saturation bands were used\[[@B8]\]. For the quantification of subcutaneous and visceral adipose tissue (VAT and SAT), a 3D GRE T1-weighted sequence on an axial plane (TR4.1, TE 1.1, flip angle 15°, matrix 320 × 192, section thickness 6 mm reconstructed 3 mm, intersection gap 0) was acquired using the IDEAL imaging and Dixon method, which enabled the separation between water and fat components using the chemical shift MR technique.

Quantitative analysis
---------------------

Images from multiple-echo GRE sequencing were subsequently analyzed with software provided by the manufacturer (Functool, GE Healthcare, Milwaukee, WI, United States); this procedure has been previously published\[[@B16]\]. A ROI measuring 2-3 cm in diameter was drawn at the same site as the voxel used for 1H-MRS to avoid extrahepatic fat and large vessels. Magnetic resonance spectra were reconstructed on a dedicated workstation using the SAGE Dev2 0017.1 software (General Electric Healthcare, Milwaukee, WI, United States). Raw data were zero-filled once, and no filter was used. Spectra were referenced to residual water and the dominant methylene lipid (-CH3 and -CH2) peak at δ 4.8-5.2 and δ 0.9-1.1 and 1.3-1.6 and 2.1-2.3, respectively. The fat fraction percentage (FF) was defined as follows: FF = FA/(FA + WA) x 100, where FA is the area under the fat peak and WA is the area under the water peak. The fat-only dataset from the T1-weighted sequence was transferred to a personal computer and analyzed using commercially available software (Slice-O-Matic; Tomovision Inc, Montreal Canada), the procedure for which has been described elsewhere\[[@B17],[@B18]\]. Briefly, SAT and VAT were calculated from 5 images extending from 5 cm below L4-L5 to 15 cm above L4-L5. A free-form ROI and manual thresholding were used to select tissue of fat within the subcutaneous and visceral adipose tissue (Figure [1](#F1){ref-type="fig"}).

![Subcutaneous and visceral fat measurement technique. A: Sagittal T1-weighted localizer MR image used to select levels for analysis (L1-L2, L2-L3, L3-L4, L4-L5, L5-S1); B: Axial T1-weighted MR image with water suppression at the L4-L5 level. Contrast was manually adjusted to select signal from subcutaneous (red) and visceral (green) adipose tissue. Area of this fat was calculated by the workstation and summarized with that of other levels.](WJG-22-8812-g001){#F1}

Histopathologic analysis
------------------------

With ultrasound guidance and within two weeks of the MR examination, a percutaneous needle liver biopsy was performed using an 18-gauge needle, with the patients under local anesthesia. To obtain an adequate sample, biopsy specimens were obtained twice from all patients at two different sites in the right hepatic lobe (VI and VII segments). Liver specimens that were at least 1.5 cm in length and contained at least 10-11 complete portal tracts were considered to be adequate for histological assessment. Liver steatosis was determined by estimating the percentage of fat-containing hepatocytes on hematoxylin-eosin-stained specimens. The grading system for liver steatosis was based on the NASH Clinical Research Network criteria\[[@B19]\]: grade 0, less than 5% steatosis; grade 1, 6%-33% steatosis; grade 2, 34%-66% steatosis; and grade 3, greater than 66% steatosis. The grading system incorporates the accepted normal value for histopathologic liver fat, which is less than 5%, and it is the standard applied in the clinical assessment of severity of liver steatosis by hepatologists and gastroenterologists.

Statistical analysis
--------------------

To estimate the proper sample size in the correlation between the MR imaging and liver biopsy, a power analysis was conducted, considering a coefficient correlation of 0.6, α error= 0.05 and power 1-β = 0.90; the number of subjects was 21. Receiver operating characteristic (ROC) curve analysis was used to determine the best cut-off values for MRS and MRI-PDHFF between the control group and children with NAFLD. The Pearson correlation coefficientwas calculated among histology, MRS and MRI-PDHFF We also estimated agreement by using the 95% limit-of-agreement method developed by Bland and Altman\[[@B20]\]. An analysis of the study population and control groups was performed to determine the median ± SD, and comparisons were made using the Mann-Whitney *U* test. Multivariate analysis of the continuous variables was performed to evaluate which variables were useful for predicting liver steatosis. A *P* value less than 0.05 was considered to indicate significant difference. Statistical analysis was performed using the MedCalc Software (V.13.1.2, Acacialaan 22 m 8400, Onsted, Belgium), except for the multivariate analysis, which was calculated using the JMP software (JMP.11, SAS Institute Inc., Cary, NC, United States).

RESULTS
=======

The clinical characteristics of the study population and control group are presented in Table [1](#T1){ref-type="table"}.

###### 

Clinical analysis and anthropometry of the study population and the control group

                  **Patients with NAFLD**                   **Control group**                                     
  --------------- ----------------------------------------- ------------------- --------------- -------- -------- --------------
  BMI             28.7[1](#T1FN1){ref-type="table-fn"}      4.07                26.2-29.58      23.75    3.5      21.86-25.84
  ALP             185                                       104.54              122.21-244.81   219.0    103.00   136.13-303.8
  ALT             31                                        52.21               30-59.5         16.5     50.7     15-20.45
  AST             25                                        25.78               21.14-30.85     22       25.21    20-26
  Bilirubin       0.53                                      0.4074              0.38-0.68       0.59     0.21     0.37-0.67
  γ-GT            21                                        12.24               17.14-28.97     11       9.98     10-12
  Insuline        17.6[1](#T1FN1){ref-type="table-fn"}      11.46               12.12-24.14     11.6     3.4      8.17-12.34
  Cholesterol     154                                       38.56               130.44-168.55   142.5    28.8     136-167
  Blood glucose   85                                        7.08                83.14-89.70     83       3.6      81-84
  Triglycerides   77                                        68.86               68.68-114.65    60.5     24.64    50-84.45
  VAT             368.35[1](#T1FN1){ref-type="table-fn"}    258.23              334.9-501.7     275.9    76.02    252.4-299.9
  SAT             1949.22[1](#T1FN1){ref-type="table-fn"}   1184.9              1743.6-2886.0   1352.9   746.95   840.3-1539.4

Significantly higher values of BMI (0.0002), VAT (\< 0.0001), SAT (0.0001), ALT (\< 0.0001) and Insulin (0.0008) were reported. γ-GT: γ-glutamyl transferase; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Of the 27 patients who underwent liver biopsy, 11 (40.7%) children demonstrated grade 1 steatosis, 9 (33.3%) children demonstrated grade 2 and 7 (26%) demonstrated grade 3 (mean, 43.3% ± 26; range, 10%-90%). The mean lipid content for MRS was 30% ± 18 (median, 30%; range, 5%-66%), whereas the MRI-PDFF mean fat fraction was 11% ± 7 (median, 10%; range, 1%-33%) (Figure [2](#F2){ref-type="fig"}). The following HFF values were recorded in the control group: MRS (mean, 4.4% ± 2.5; median, 4%; range, 0.8%-13%) and MRI-PDFF (mean, 2.5 ± 2; median, 1.9%; range, 0.7%-11%).

![Mean lipid content for MR-Spectroscopy. A-C: MRI-PDFF reveals a hepatic fat fraction of 7%, MRS quantified 6.5% of liver steatosis and histological analysis 30% of liver steatosis; D-F: Severe hepatic steatosis in a 8-year-old girl: MRII-PDFF 25%, MRS 50% and histologic analysis 90% of liver steatosis respectively.](WJG-22-8812-g002){#F2}

The ROC curve analysis suggested a cut-off value of 6% for MRS to discriminate between patients with and without steatosis (sensitivity, 92.6%; specificity, 95.7%; 6 false positive calls); conversely, MRI-PDFF suggested a cut-off value of 3.5% (sensitivity, 89%; specificity, 88%; 4 false positive calls) (Figure [3](#F3){ref-type="fig"}).

![Receiver operating characteristic curve analysis of MR Spectrscopy (A) and MR imaging-PDFF (B) for discrimination of healthy from non-alcoholic fatty liver disease children.](WJG-22-8812-g003){#F3}

For MR spectroscopy, compared with the histology results, the Pearson test revealed a correlation of 0.68, (*P* = 0.0001) MRI-PDFF showed slightly lower values of 0.63, 0 (*P* = 0.0005).

Excellent correlation was reported between the MR techniques (ρ 0.81, *P* \< 0.0001). Bland Altman plot reveals all points within were within the 95% limit of agreement, a possible bias encountered in the evaluation of MR-PDFF at medium and high level of hepatic steatosis (Figure [4](#F4){ref-type="fig"}).

![Evaluation of magnetic resonance imagingestimated-proton density fat fraction at medium and high level of hepatic steatosis. A, B: Differences between liver fat fraction estimated by using ^1^H MR spectroscopy and triple-echo sequence compared with histology were plotted against means, with 95% confidence intervals (Bland-Altman plot); C: All data points were within limits of agreement (dotted lines), corresponding to 1.96 SDs from mean. MRS: MR-Spectroscopy.](WJG-22-8812-g004){#F4}

Compared to the control group, significantly higher BMI (0.0002), VAT (\< 0.0001), SAT (0.0001), ALT (\< 0.0001) and insulin (0.0008) values were reported in the study population. Multivariate analysis of the quantitative variables demonstrated good correlation among VAT, SAT, BMI and insulin in terms of predicting liver steatosis (0.80, 0.51, 0.50 and 0.52, respectively).

DISCUSSION
==========

Our results suggest that MRS is an accurate, non-invasive diagnostic technique for quantifying liver steatosis in a pediatric population and that MRI-PDFF is a feasible alternative technique. For MRS, the same cut-off value of 5% can be used to diagnosis liver steatosis in adolescents and adults; in contrast, when MRI-PDFF is used to quantify liver steatosis, a cut-off value of 3.5% is more appropriate. For clinical and morphologic analyses, the BMI, VAT, SAT and insulin levels should be jointly considered promising tools for predicting liver steatosis.

In a pediatric population, precise measurement of the degree of liver steatosis is of clinical interest because it has demonstrated an association with subclinical signs of atherosclerosis and changes in myocardial functions\[[@B21]-[@B24]\]. At present, no laboratory test can be used for the non-invasive quantification of liver steatosis, and ALT values may be elevated only in severe cases\[[@B25]\]. Although our analysis reported significantly higher levels of ALT and insulin in predicting liver steatosis, only in severe cases were the results beyond normal ranges. Anthropometry data revealed significantly higher BMI, SAT and VAT values in children with NAFLD, as previously described in the literature\[[@B26],[@B27]\]; unfortunately, multivariate analysis demonstrated only moderate to good values in predicting liver steatosis (range, 0.80 - 0.50).

Among the imaging modalities, MRS can provide a reliable estimation of the weight fraction of liver fat content, and it is now considered to be the most accurate non-invasive method; for these reasons, it is used extensively in published reports\[[@B28]-[@B32]\]. In addition, in our experience, MRS demonstrated excellent correlation with liver biopsy, with good concordance. However, MRS is an expensive and primarily research-based tool that is not always available\[[@B33],[@B34]\]. MRI-PDFF has been proposed as a feasible and simple alternative method for quantifying liver steatosis\[[@B10],[@B11],[@B35]-[@B37]\]. Our data demonstrated good correlation between histology. However a probable error should be develop in the differentiation between moderate and high grade of steatosis: this limit of chemical shift technique is attributed to the presence of both water and fat (fat-water signal dominance ambiguity) in the single voxel and it is not of clinical relevance for patients treatment and managment\[[@B38],[@B39]\]. MR-PDFF suggests a lower threshold (3.5%) to define hepatic steatosis in children, in agreement with a recent publication by Rehm et al\[[@B40]\]. Our multiple-echo sequence has several advantages over MRS. First, the acquisition time is short, easily fitting within a breath hold. Second, the fat content can be measured throughout the liver instead of in only one voxel or a few voxels; this point is of major importance because fat distribution is often heterogeneous. Third, no spatial miss-registration errors occur because the OP and IP images are acquired simultaneously. Fourth, post-processing is considerably easier and faster than with MRS.

Some study limitations should be noted. First, the site-to-site reproducibility of our technique was evaluated only in segment VII. Second, our control group did not have histologically confirmed healthy livers because it would have been unethical to subject normal individuals to liver biopsy assessments. Thirdly, the three parameters (MRS, MR-PDFF and histology) tested in our study assess different aspects of steatosis. Histology reveals the percentage of hepatocytes that contain vesicles of fat, MR-PDFF determines the proportion of mobile protons contained within fat molecules and MRS shows the peaks of methyl and methylene (-CH2 and CH3) protons in the triglyceride molecule.

Finally, Bland-Altman plot analysis demonstrates a difficulty of MR-PDFF in the differentiation between moderate to severe steatosis; however this drawback has not clinical relevance becasuse treatment and managmetn of patients is quite similar.

In conclusion, MRS was confirmed as the most accurate non-invasive method for quantifying liver steatosis in obese children.

Multiple-echo gradient-echo MR sequence may also be an easily and rapidly performed technique used to quantify liver steatosis in a pediatric population; this technique demonstrated excellent agreement with MRS and should be considered as reference standard in longitudinal studies or clinical trials. Together, BMI, VAT, SAT and insulin measurements provide the most powerful test for predicting liver steatosis. Further studies should be conducted to better match data from histological and MRI analyses and to establish MRI thresholds for different grades of steatosis.
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